drugset
drugset / Trial / NCT02355509

Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients

NCT02355509 ↗

Phase 4 Completed 21 enrolled National Institute of Medical Sciences and Nutrition Salvador Zubiran
RandomizedParallel-groupTriple-blindTreatment

Summary

Is a randomized, double-blind, placebo-controlled trial to determine the behavior of hyperglycemia and postprandial lipemia after a standard mixed meal load in patients with carbohydrate intolerance treated with acarbose.

Timeline

Start
2010-01
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 150 mg —

Indications

glucose intolerance hyperglycemia